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Abstract 
Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient 
treatment of non-Hodgkin’s lymphoma (NHL). This study aimed to assess the efficacy and toxicity of dose-adjusted 
CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients. Fac-
tors affecting the collection of CD34+ cells were also explored.
Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients 
who expressed CD20 and were financially eligible received R-CHOP for autologous peripheral blood stem cell (APBSC) 
mobilization; the remaining 25 patients received CHOP.
Results: The median CD34+ cell yield was 7.01 × 106 cells/kg body weight (range 1.49–28.39 × 106 cells/kg body 
weight), with only two patients failing to meet the target CD34+ cell harvest of ≥2.0 × 106 cells/kg body weight. 
The median number of apheresis procedures per patient was 1 (range 1–3). The APBSC mobilization yield of the 
CHOP group appeared to be higher than that of the R-CHOP group (P = 0.005), whereas the success rate was similar 
between groups. R-CHOP elevated the complete response (CR) rate in B cell lymphoma patients as compared with 
CHOP (P = 0.01). No significant differences in toxicity or engraftment were observed between the two groups.
Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy effectively mobilized APBSCs 
in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for 
patients with B-cell lymphoma.
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Background
Autologous stem cell transplantation (ASCT) provides 
hematopoietic support after high-dose chemotherapy 
and is widely used to treat non-Hodgkin’s lymphoma 
(NHL). Successful stem cell collection is a prerequi-
site for ASCT. The combination of chemotherapy with 
recombinant human granulocyte colony-stimulating fac-
tor (rhG-CSF) is a commonly used mobilization strategy, 
resulting in higher CD34+ cell yields than mobilization 
with rhG-CSF alone [1, 2]. This approach also purges the 
mobilized tumor cells, reducing the tumor burden, and 
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leads to chemosensitivity before transplantation. Nev-
ertheless, additional study is required to determine the 
optimal mobilization regimen in terms of safety, progeni-
tor yield, engraftment, and contamination with tumor 
cells [3].
Various chemomobilization regimens have been widely 
used in patients with lymphoma. High-dose cyclophos-
phamide, high-dose etoposide, and platinum-based 
chemotherapies such as ifosfamide, carboplatin, etopo-
side (ICE); cisplatin, cytarabine, dexamethasone (DHAP); 
and etoposide, methylprednisolone, cytarabine, cisplatin 
(ESHAP) are commonly used in combination with rhG-
CSF [4]. Nevertheless, all current regimens fail to mobi-
lize a sufficient number of hematopoietic stem cells to 
proceed to transplantation in 5–40% of patients [1, 2, 5], 
and some patients relapse after ASCT due to residual dis-
ease after high-dose chemotherapy or contamination of 
the mobilization product with tumor cells [6, 7]. There-
fore, additional research is required to determine a more 
effective mobilization regimen to improve patients’ out-
come and survival.
Rituximab is commonly used in the first- or second-
line therapy of NHL patients before autologous periph-
eral blood stem cell (APBSC) mobilization as a way to 
improve the in  vivo purging of circulating lymphoma 
cells before stem cell collection [8]. However, whether 
rituximab compromises the yield of APBSCs and the 
hematopoietic recovery after ASCT remains a topic of 
debate [6, 8–15]. The regimen of cyclophosphamide, 
doxorubicin, vincristine, and prednisolone (CHOP) has 
been established as the standard treatment for NHL [16]. 
However, few studies have explored APBSC mobilization 
following CHOP combined with rituximab (R-CHOP) 
in high-risk NHL. Therefore, the present retrospective 
study was designed to analyze the efficacy and toxicity of 
dose-adjusted CHOP or CHOP-like regimen alone or in 
combination with rituximab for APBSC mobilization and 




Patients diagnosed with stage III/IV, highly aggressive 
B-cell lymphoma or T-cell lymphoma between August 
2000 and June 2013 were identified from a database of 
prospective observational research on ASCT in malig-
nant lymphoma. The analysis was approved by the 
Institutional Review Board of the Cancer Institute/
Hospital, Chinese Academy of Medical Science and 
Peking Union Medical College (CAMS and PUMC). 
All patient diagnoses were histologically confirmed at 
the Department of Pathology, Cancer Institute/Hospi-
tal, CAMS and PUMC. All patients were required to be 
younger than 65 years old and to have adequate organ 
function. Patients were excluded if they had human 
immunodeficiency virus (HIV) infection, central nerv-
ous system (CNS) disease, active hepatitis B or C, or 
grade ≥2 peripheral neuropathy. Patients were staged 
according to the Ann Arbor Classification before 
mobilization. Staging procedures included physi-
cal examination, reporting of B symptoms, computer 
tomography (CT) or positron emission tomography 
(PET)-CT scans, and bone marrow biopsy. Because 
this was a retrospective study, the use of PET-CT to 
aid in the assessment of the response had varied over 
time. All patients exhibited at least a partial response 
(PR) at the time of mobilization and were on their first 
mobilization attempt.
APBSC mobilization
Patients were treated with induction chemotherapy regi-
mens such as CHOP; bleomycin, epirubicin, cyclophos-
phamide, vincristine, plus prednisone (BACOP); and 
prednisone, doxorubicin, cyclophosphamide, etoposide, 
cytarabine, bleomycin, vincristine, plus methotrexate 
(ProMACE/CytaBOM) before mobilization.
Mobilization chemotherapy included dose-adjusted 
CHOP or CHOP-like regimens alone (CHOP group) 
or in combination with rituximab (R-CHOP group) 
according to CD20 expression and patients’ finan-
cial circumstances. The dose-adjusted CHOP regimen 
consists of cyclophosphamide (1–2 g/m2 per day), vin-
cristine (1.4 mg/m2 per day, maximum 2 mg), and dox-
orubicin (50  mg/m2 per day) or epirubicin (75  mg/m2 
per day) all on day 1 and prednisone (100 mg/day) on 
days 1–5. The CHOPE regimen consists of CHOP plus 
etoposide (100–200  mg/m2 per day) on days 1–3. The 
BACEP regimen consists of bleomycin (15 mg/day) on 
days 3 and 10, epirubicin (75 mg/m2 per day) on day 1, 
cyclophosphamide (1 g/m2 per day) on day 1, etoposide 
(100 mg/m2 per day) on days 1–3, prednisone (100 mg/
day) on days 1–5. Rituximab was administered at 
375 mg/m2 per day on the day before mobilization, day 
7 after mobilization, the day before APBSC infusion, 
and day 8 after infusion [17].
The first dose of rhG-CSF was administered subcu-
taneously at a fixed dose of 300 µg/day (150 µg/day for 
patients weighing less than 45  kg) beginning on the 
day when the white blood cell (WBC) count first rose 
after the nadir following chemotherapy, continuing 
until the day before the last apheresis. To determine 
the first day of apheresis, the WBC count and the per-
centage of CD34+ cells in peripheral blood (defined as 
the ratio of CD34+ cells to mononuclear cells [MNCs]) 
were monitored daily after chemotherapy. When the 
WBC count exceeded 10  ×  109/L, the MNC count 
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exceeded 2  ×  109/L, and the percentage of CD34+ 
cells in peripheral blood exceeded 1% [18], continu-
ous APBSC collection was conducted daily with a 
CS-3000 Plus blood cell separator (Baxter Health-
care Corp., Deerfield, IL, USA) until a target collec-
tion of at least 2  ×  106 CD34+ cells/kg body weight 
or 4 ×  108 MNCs/kg body weight was achieved. The 
blood volume processed by each single apheresis was 
110–150 mL/kg body weight at a speed of 40–70 mL/
min. Venous access was obtained by a double lumen 
catheter (Arrow International Inc., Reading, PA, USA) 
placed in a femoral vein [17, 18]. After mobilization, 
the amount of CD34+ cells in the apheresis product 
was measured after each collection by flow cytometry 
using a class III monoclonal antibody (Becton–Dickin-
son, Franklin Lakes, NJ, USA) [19]. Dimethylsulfoxide 
was added to the products at a final concentration of 
10% to protect the cells from the stress or death caused 
by cryopreservation. The products were stored at 
−80°C with an uncontrolled freezing rate. Twenty-four 
hours later, the samples were transferred into a liquid 
nitrogen container (Thermo Scientific, Waltham, MA, 
USA) and stored at −196°C [18].
Successful mobilization was defined as the collection of 
a minimum of 2 × 106 CD34+ cells/kg body weight in a 
single mobilization. Optimal mobilization was defined as 
5 × 106 CD34+ cells/kg body weight collection in a sin-
gle mobilization [20]. Failed mobilization was defined as 
the failure to collect at least 2 × 106 CD34+ cells/kg body 
weight by aphaeresis.
Conditioning regimen and engraftment
The conditioning regimens were BEAC [carmustine 
(300 mg/m2, day −5), etoposide (800 mg/m2, days −4 to 
−2), cytarabine (1600 mg/m2, days −4 to −2), cyclophos-
phamide (1.8 g/m2, days −6 to −5)], BEAM [carmustine 
(300 mg/m2, day −5), etoposide (800 mg/m2, days −4 to 
−2), cytarabine (1600 mg/m2, days −4 to −2), melphalan 
(140–160 mg/m2 for oral administration, day −6)], CBV 
[cyclophosphamide (1.8  g/m2, days −3 to −2), carmus-
tine (450–600 mg/m2, day −7), etoposide (900–1600 mg/
m2, days −6 to −4)], and CE-TBI [cyclophosphamide 
(1.8  g/m2, days −3 to −2), etoposide (750  mg/m2, days 
−6 to −4), total body irradiation (800–900 Gy, day −7)]. 
The day APBSCs were infused was defined as day 0. rhG-
CSF (300 µg/day) was administered after APBSC infusion 
on day 6 and was continued until the neutrophil count 
recovered to at least 0.5  ×  109/L on two consecutive 
days, defined as neutrophil engraftment. Platelet (PLT) 
engraftment was taken as the time when the PLT count 
recovered to more than 50 × 109/L for two consecutive 
days without transfusion support.
Evaluation of mobilization responses, toxicities, 
and survival
Response to treatment was evaluated according to the 
International Workshop Criteria [21], and all adverse 
reactions were recorded and graded according to the 
National Cancer Institute criteria [22]. Overall survival 
(OS) and progression-free survival (PFS) were measured 
from the date of mobilization to the end of follow-up. 
Routine follow-up by imaging analysis was performed 
every 3 months for the first 2 years, every 6 months for 
the next 3 years, and then annually or whenever clinically 
indicated. The last follow-up was on November 30, 2013.
Statistical methods
All calculations and statistical analyses were conducted 
using SPSS software (version 19.0, SPSS Inc., Chicago, 
IL, USA). For quantitative variables, medians, ranges, and 
proportions were determined and analyzed by descrip-
tive statistics and frequency analysis. Comparisons of 
categorical variables between groups were tested by the 
Chi square test or Fisher’s exact test, and continuous var-
iables were compared between two groups by the Mann–
Whitney U test. For univariate analysis, a Spearman 
correlation analysis was conducted for continuous vari-
ables, and a Mann–Whitney U test was conducted for 
categorical variables to explore the effect of pre-mobiliza-
tion factors on the yield of CD34+ cells. A linear stepwise 
regression was used for multivariate analysis. Survival 
data were analyzed using the Kaplan–Meier method, and 
survival curves were compared using the log-rank test. A 
two-tailed P value of <0.05 was considered significant.
Results
Patients
A total of 39 patients were included in the analysis, 
with a median age of 33 (range 11–57) years. CHOP or 
CHOP-like regimens were administered for APBSC 
mobilization. Of the 25 patients in the CHOP group, 15 
received CHOP regimen, 8 received CHOPE regimen, 
and 2 received BACEP regimen; of the 14 patients in 
the R-CHOP group, 11 received R-CHOP regimen, and 
3 received R-CHOPE regimen. The median number of 
chemotherapy cycles prior to mobilization was 4 (range 
2–6). As a result, 17 patients (43.6%) achieved a CR, 
and 22 (56.4%) achieved a PR prior to mobilization. The 
R-CHOP and CHOP groups were well matched in terms 
of age, sex, Ann Arborstage, age-adjusted international 
prognostic index (aaIPI), previous chemotherapy cycles, 
and disease status at mobilization (Table  1). All T-cell 
lymphoma patients were included in the CHOP group, 
though tumor origin did not affect the CD34+ cell mobi-
lization yield (P = 0.061).
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APBSC mobilization
For the 39 patients, the median CD34+ cell yield was 
7.01 × 106 cells/kg body weight, with only 2 patients fail-
ing to meet the target CD34+ cell harvest of ≥2.0 × 106 
cells/kg body weight (1.46  ×  106 and 1.61  ×  106 cells/
kg body weight, respectively), both of whom underwent 
successful ASCT. The optimal mobilization was achieved 
in 27 patients (69.2%), and 19 of them only underwent 
one apheresis procedure with a median CD34+ cell 
collection of 7.48 × 106 cells/kg body weight (range 5.03–
18.50 × 106 cells/kg body weight).
The time from mobilization to apheresis was longer in 
the R-CHOP group than in the CHOP group (P = 0.032), 
whereas the median number of apheresis procedures 
was similar between the two groups. The percentage of 
CD34+ cells in peripheral blood by the first apheresis, 
the WBC count, and the mobilization yield of CD34+ 
cells were significantly lower in the R-CHOP group than 
in the CHOP group. Excluding the confounding factor 
tumor origin, the mobilization yield of CD34+ cells for 
B-cell lymphoma patients was still significantly higher in 
the CHOP group than in the R-CHOP group (P = 0.029). 
However, the rate of optimal mobilization between the 
two groups was similar (P = 0.075). More details are out-
lined in Table 2.
Toxicity
The most common toxicity was hematologic for both the 
CHOP and R-CHOP mobilization regimens: 20 (51.3%) 
patients experienced grade 4 neutropenia, 12 (30.8%) 
developed febrile neutropenia, and 3 (7.7%) had grade 
3/4 thrombocytopenia. Anemia and vomiting were com-
mon but mild. Grade 3 anemia and vomiting occurred 
in 2 and 3 patients, respectively. PLT transfusions were 
administered to 3 patients, and a red blood cell (RBC) 
transfusion was only given to 1 patient. However, no fatal 
toxicities (grade ≥4) or transplantation-related mortal-
ity were observed in this study, and all the complications 
were mild and reversible within 24–48 h in all cases.
The neutrophil nadir from the first day of mobilization 
induced by the R-CHOP regimen occurred later than 
that induced by the CHOP regimen (P = 0.042), and the 
period from mobilization to the date of the PLT nadir 
was longer in the R-CHOP group than in the CHOP 
group (P  =  0.008). However, the median neutrophil 
count and PLT count at the nadir were similar between 
the two groups. No significant differences in mobilization 
toxicities such as vomiting, diarrhea, and elevated ala-
nine transaminase (ALT) were observed between the two 
groups. More details are outlined in Table 3.
Conditioning regimens and engraftment
All 39 patients received transplantation, even the 2 
patients who failed APBSC mobilization. Of the 39 
patients, 28 (71.8%) received BEAC, 6 (15.4%) received 
BEAM, 3 (7.7%) received CBV, and 2 (5.1%) received CE-
TBI as conditioning regimens.
The median time from APBSC infusion to reaching a 
WBC count of at least 1.5 ×  109/L for two consecutive 
days was 11 days (range 8–14 days), and the median time 
for PLT recovery was 12  days (range 7–32  days). The 
median duration of rhG-CSF support was 7 days (range 
Table 1 Baseline characteristics of  39 patients with  high-
risk non-Hodgkin’s lymphoma
R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine, 
and prednisolone (CHOP) or CHOP-like regimen; CHOP, CHOP or CHOP-like 
regimen without rituximab; ECOG Eastern Cooperative Oncology Group; LDH 
lactate dehydrogenase; aaIPI age-adjusted International Prognostic Index; CR 
complete response; PR partial response; NA not available
Characteristic R-CHOP [cases (%)] CHOP [cases (%)] P value
Total 14 25
Sex 0.673
 Male 8 (57.1) 16 (64.0)
 Female 6 (42.9) 9 (36.0)
Tumor origin <0.001
 B-cell 14 (100.0) 8 (32.0)
 T-cell 0 15 (60.0)
 NA 0 2 (8.0)
Ann arbor stage 0.119
 I/II 1 (7.1) 8 (32.0)
 III/IV 13 (92.9) 17 (68.0)
ECOG score 0.289
 <2 13 (92.9) 23 (92.0)
 ≥2 1 (7.1) 2 (8.0)
LDH level (IU/L) 0.328
 >225 9 (64.3) 12 (48.0)
 ≤225 5 (35.7) 13 (52.0)
B symptoms 0.089
 No 5 (35.7) 16 (64.0)
 Yes 9 (64.3) 9 (36.0)
Bulky disease 0.431
 No 6 (42.9) 14 (56.0)
 Yes 8 (57.1) 11 (44.0)
Extranodal invasion 0.652
 No 3 (21.4) 7 (28.0)
 Yes 11 (78.6) 18 (72.0)
aaIPI 0.096
 0–1 4 (28.6) 15 (60.0)
 2–3 10 (71.4) 10 (20.0)
Disease status before mobilization 0.201
 CR 8 (57.1) 9 (36.0)
 PR 6 (42.9) 16 (64.0)
Previous radiation 
therapy
0 2 (8.0) 0.528
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3–25  days). No differences were observed in the WBC 
and PLT recovery time between the two groups (Table 4).
Responses and survival
Of the 22 patients who failed to reach a CR before mobi-
lization, 1 progressed and 8 maintained their PR status 
in the CHOP group, 13 converted to CR after mobiliza-
tion, with 7 in the CHOP group and 6 in the R-CHOP 
group. The CR rate of patients with B-cell lymphoma 
was higher in the R-CHOP group than in the CHOP 
group (P  =  0.010, Table  4). None of the 17 patients 
who achieved a CR before mobilization relapsed during 
mobilization.
The median follow-up time was 56  months (range 
2–162  months); the 5-year PFS and OS rates for all 
patients were 65.7% (Fig. 1a) and 75.6% (Fig. 1b), respec-
tively. No significant differences in OS or PFS were 
observed between the R-CHOP and CHOP groups.
Factors associated with mobilization yield
In the univariate analysis, we observed a significant lin-
ear correlation between the percentage of CD34+ cells 
Table 2 Outcomes and efficacy of mobilization in 39 patients with high-risk non-Hodgkin’s lymphoma
rhG-CSF recombinant human granulocyte colony-stimulating factor, WBC white blood cell. Other abbreviations as in Table 1
a The values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses
Parameter All patients (n = 39) R-CHOP (n = 14) CHOP (n = 25) P value
Time from mobilization chemotherapy to rhG-CSF support (days)a 9 (6–15) 12.5 (9–15) 12 (6–15) 0.082
Duration of rhG-CSF support (days)a 5 (3–10) 5 (3–9) 5 (4–10) 0.343
Time from mobilization chemotherapy to apheresis (days)a 16 (12–20) 16.5 (15–18) 16 (12–20) 0.032
Percentage of CD34+ cells in peripheral blood on the first day of apheresis (%)a 2.43 (0.36–7.50) 1.35 (0.36–3.41) 3.14 (1.14–7.50) 0.002
Peripheral blood WBC count on the first day of apheresis (×109/L)a 14.30 (3.55–43.20) 10.35 (3.55–43.20) 17.15 (5.56–41.60) 0.031
Number of apheresis proceduresa 1 (1–3) 1 (1–2) 1 (1–3) 0.593
CD34+ cells collected on day 1 (×106 cells/kg body weight)a 5.79 (0.40–18.50) 4.83 (1.03–8.11) 7.07 (0.40–18.50) 0.016
CD34+ cells collected in total (×106 cells/kg body weight)a 7.01 (1.49–28.39) 5.01 (1.49–13.40) 8.25 (1.61–28.39) 0.005
CD34+ cells collected per apheresis (×106 cells/kg body weight)a 5.97 (0.75–18.50) 4.83 (0.75–8.11) 7.31 (0.81–18.50) 0.014
Optimal mobilization of CD34+ cell collection [cases (%)] 27 (69.2) 7 (50.0) 20 (80.0) 0.075
Successful mobilization of CD34+ cells [cases (%)] 37 (94.5) 13 (92.9) 24 (96.0) 1.000
Table 3 Toxicities after mobilization in 39 patients with high-risk non-Hodgkin’s lymphoma
PLT platelets, ALT alanine transaminase. Other abbreviations as in Tables 1 and 2
a The values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses
Parameter R-CHOP (n = 14) CHOP (n = 25) P value
Time from mobilization to the nadir of WBC (days)a 12 (9–14) 11 (0–16) 0.104
WBC count at nadir (×109/L)a 1.24 (0.23–2.60) 1.30 (0.06–3.70) 0.856
Time from mobilization to the nadir of neutrophils (days)a 12.5 (9–15) 11 (5–15) 0.042
Neutrophil count at nadir (×109/L)a 0.46 (0–1.60) 0.50 (0–2.41) 0.915
Time from mobilization to the nadir of PLT (days)a 14.5 (11–19) 13.0 (6–16) 0.008
PLT count at nadir (×109/L)a 97.5 (51–171) 97.0 (12–193) 0.797
PLT transfusions [cases (%)] 1 (7.1) 2 (8.0) 0.748
Vomiting [cases (%)] 0.805
 Grade 1/2 8 (57.1) 18 (72.0)
 Grade 3 1 (7.1) 2 (8.0)
Febrile neutropenia [cases (%)] 3 (21.4) 9 (36.0) 0.477
Diarrhea [cases (%)] 0 4 (16.0) 0.387
ALT elevation [cases (%)] 5 (35.7) 15 (60.0) 0.234
Anemia [cases (%)] 0.212
 Grade 1/2 7 (50.0) 20 (80.0)
 Grade 3 1 (7.1) 1 (4.0)
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in peripheral blood on the first day of apheresis and the 
total CD34+ cell yield (Spearman r =  0.593, P  <  0.001, 
Fig.  2a). Similarly, younger age (Spearman r  =  −0.379, 
P  =  0.017, Fig.  2b) and male gender (P  =  0.035) were 
associated with better CD34+ cell collection. Previous 
chemotherapy cycles (Spearman r = −0.337, P = 0.036), 
duration of rhG-CSF support for mobilization (Spearman 
r = −0.425, P =  0.008), and time from mobilization to 
apheresis (Spearman r = −0.453, P = 0.004) were nega-
tively correlated with CD34+ cell collection. However, 
Table 4 Post-transplantation engraftment and responses in 39 patients with high-risk non-Hodgkin’s lymphoma
APBSC autologous peripheral blood stem cells, rhG-CSF recombinant human granulocyte colony-stimulating factor; CR, complete response. Other abbreviations as in 
Tables 1, 2 and 3
a The values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses
b All the 14 patients in R-CHOP group and 8 patients in CHOP group had B-cell lymphoma
Parameter R-CHOP (n = 14) CHOP (n = 25) P value
Time from APBSC infusion to WBC engraftment (days)a 11 (9–13) 11 (8–14) 0.692
Time from APBSC infusion to PLT engraftment (days)a 12.5 (7–18) 12.0 (9–32) 0.988
Duration of rhG-CSF support from APBSC infusion to engraftment (days)a 8.5 (4–12) 7.0 (3–25) 0.410
CR for B-cell lymphoma [cases (%)]b 14 (100) 4 (50) 0.010
Fig. 1 Survival curves of all patients with high-risk non-Hodgkin’s lymphoma mobilized by cyclophosphamide, doxorubicin, vincristine, and predni-
solone (CHOP) alone or in combination with rituximab (R-CHOP). a Progression-free survival; b overall survival
Fig. 2 Factors associated with mobilization yield in patients with high-risk non-Hodgkin’s lymphoma. a Positive correlation between total CD34+ 
cell yield and the percentage of CD34+ cells in peripheral blood on the first day of apheresis. b Negative correlation between total CD34+ cell yield 
and age
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only age (P = 0.011) and the percentage of CD34+ cells in 
peripheral blood on the first day of apheresis (P < 0.001) 
had predictive values for the total CD34+ cell yield in 
multivariable analysis (Table 5).
Discussion
In the present study, the dose-adjusted CHOP and 
R-CHOP regimens were shown to be feasible and well 
tolerated in mobilizing sufficient APBSCs in NHL 
patients. Of this study population, 95% of patients were 
successful in achieving the target CD34+ cell harvest of 
≥2  ×  106 cells/kg body weight, with a median CD34+ 
cell yield of 7.01  ×  106 cells/kg body weight (range 
1.49–28.39  ×  106 cells/kg body weight). These results 
were superior to the published results for the tradi-
tional regimen of ICE combined with rituximab (88% 
success rate; median, 6.3  ×  106 cells/kg body weight; 
range 0–15.6 × 106 cells/kg body weight) [23] or etopo-
side (94% success rate; median, 6.2 ×  106 cells/kg body 
weight; range 0–27.6  ×  106 cells/kg body weight) [24]. 
Possibly because of the excellent stem cell mobilization, 
all patients in our study successfully proceeded to trans-
plantation. Although 51% of patients developed grade 
4 neutropenia and 31% of patients experienced febrile 
neutropenia, no grade 4 toxicities or treatment-related 
deaths were observed, indicating the safety of this regi-
men. A PLT transfusion was given in 7% of patients, and 
an RBC transfusion was given in 2% of patients. These 
rates were significantly lower than those observed for 
patients mobilized by other regimens, such as etoposide 
(30 and 30%) [24] and ESHAP regimens (12 and 12%) [6].
The mobilization yield of CD34+ cells in the CHOP 
group appeared to be higher than that in the R-CHOP 
group, and this phenomenon was previously explained by 
the biological theory that perturbation of stromal-derived 
factor-1 during B-cell recovery after rituximab treatment 
retards neutrophil egress from the marrow [9]. However, 
the disadvantage of rituximab in terms of mobilization 
yield was offset by the high rate of successful mobiliza-
tion. The efficacy of the R-CHOP regimen was similar 
to that of the CHOP regimen, with both resulting in a 
successful mobilization rate of over 90%. This finding was 
consistent with that in the study conducted by Lefrère 
et al. [8], who reported that 91 of 137 patients receiving 
rituximab exhibited a similar rate of successful mobiliza-
tion as the non-rituximab group. When considering the 
safety and efficacy of ASCT, it is important to note that 
serious infections have been reported with rituximab 
administration because of delayed neutrophil and PLT 
recovery and late-onset neutropenia [10–12]. Neverthe-
less, Lefrère et al. [8] suggested that rituximab combined 
with chemotherapy was safe, without excess toxicity or 
delayed ASCT engraftment. In our study, the times to 
WBC and PLT recovery after transplantation were simi-
lar between the R-CHOP and CHOP groups, as were the 
toxicity and complications. Rituximab seemed to elevate 
the CR rate (P =  0.01) in B-cell lymphoma, which may 
be consistent with the results of previous studies [10, 13, 
14]. Several other studies reported rituximab-induced 
interstitial lung disease, with some cases considered 
life-threatening [25, 26]. However, this toxicity was not 
observed in our study.
Our data showed that younger age and male gen-
der were closely related with better mobilization yield, 
in agreement with the findings of Akhtar et  al. [15]. 
Although PLT counts prior to mobilization have been 
significantly associated with the total CD34+ cell col-
lection after mobilization in some studies [15, 18, 27], 
this association was not observed in our study, perhaps 
because of the smaller number of patients enrolled in our 
study. In addition, the higher percentage of CD34+ cells 
in peripheral blood on the first day of apheresis and the 
lower number of prior chemotherapy cycles resulted in 
a better mobilization yield in our study, consistent with 
the findings in several previous studies [1, 15, 18]. In light 
of the recent development of new classes of mobiliza-
tion agents such as CXC chemokine receptor 4 (CXCR4) 
inhibitors and plerixafor, predictive factors are urgently 
needed to discern which patients are likely to benefit 
from the more efficient mobilization agents [28].
This study has several limitations. It was an uncon-
trolled, retrospective, single-center study, including 
Table 5 Multivariable analysis of the total CD34+ cell yield in 39 patients with high-risk non-Hodgkin’s lymphoma
CI confidence interval. Other abbreviation as in Table 2
Parameter Total CD34+ cell yield (×106 cells/kg body weight)
B 95% CI P value
Percentage of CD34+ cells in peripheral blood on the first day of apheresis 1.886 1.104 to 2.669 <0.001
Previous chemotherapy cycles −0.07 −1.386 to 1.245 0.914
Duration of rhG-CSF support −0.829 −1.685 to 0.028 0.058
Time from mobilization to apheresis −0.736 −1.544 to 0.073 0.073
Age −3.718 −6.521 to −0.914 0.011
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selected patients treated over many years. However, we 
consider our results to be reliable for selecting an effec-
tive chemomobilization regimen because the clinical 
characteristics that might affect the APBSC mobilization 
yield were comparable with those in other studies, and 
apheresis procedures were performed according to simi-
lar guidelines as those in other studies.
Conclusions
In conclusion, the present study showed that CHOP 
chemotherapy followed by rhG-CSF provides effective 
mobilization of APBSCs in patients with NHL and that 
the addition of rituximab to CHOP chemotherapy for 
APBSC mobilization is feasible. Prospective randomized 
trials are necessary to confirm the efficacy of this mobili-
zation regimen.
Authors’ contributions
YS made substantial contributions to conception, design and implementation 
of the study, analysis and interpretation of data, and approved the final version 
to be published. PZ collected the data, performed the statistical analysis, and 
helped to draft the manuscript. XH, SZ, PL, JY, CZ, LG, YQ, and SY selected the 
patients, participated in the design and implementation of the study, helped 
collect the data and perform the statistical analysis, and gave advice about the 
draft manuscript. XH and JY participated in the apheresis and test of CD34+ 
cells, helped collect the data and perform the statistical analysis. LZ and SZ 
participated in the nursery of patients. All authors read and approved the final 
manuscript.
Acknowledgements
This work was supported in part by Grants from National Science-Technology 
Support Plan Projects of China (2014BAI09B12), National Major Project for New 
Drug Innovation of China (2008ZX09312 and 2012ZX09303012), and the Min-
istry of Education Doctor Foundation of China (20010023018, 20050023045, 
and 200800230019).
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 4 January 2015   Accepted: 26 July 2015
References
 1. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of 
mobilization and remobilization strategies on achieving sufficient stem 
cell yields for autologous transplantation. Biol Blood Marrow Transplant. 
2008;14:1045–56.
 2. Bensinger W, DiPersio JF, MacCarty JM. Improving stem cell mobi-
lization strategies: future directions. Bone Marrow Transplant. 
2009;43:181–95.
 3. Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized 
controlled trials of hematopoietic stem cell mobilization strategies for 
autologous transplantation for hematologic malignancies. Biol Blood 
Marrow Transplant. 2012;18:1191–203.
 4. Hyun SY, Cheong JW, Kim SJ, Min YH, Yang DH, Ahn JS, et al. High-dose 
etoposide plus granulocyte colony-stimulating factor as an effective 
chemomobilization regimen for autologous stem cell transplantation in 
patients with non-Hodgkin lymphoma previously treated with CHOP-
based chemotherapy: a study from the consortium for improving survival 
of lymphoma. Biol Blood Marrow Transplant. 2014;20:73–9.
 5. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. 
Poor mobilization of hematopoietic stem cells—definitions, incidence, 
risk factors, and impact on outcome of autologous transplantation. Biol 
Blood Marrow Transplant. 2010;16:490–9.
 6. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, et al. Rituximab-ESHAP 
as a mobilization regimen for relapsed or refractory B-cell lymphomas: a 
comparison with ESHAP. Transfusion. 2007;47:1447–54.
 7. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-
López J, et al. High-risk cytogenetics and persistent minimal residual 
disease by multiparameter flow cytometry predict unsustained complete 
response after autologous stem cell transplantation in multiple myeloma. 
Blood. 2012;119:687–91.
 8. Lefrère F, Bastit-Barrau D, Hequet O, Bourin P, Mathieu-Nafissi S, Bohbot 
A, et al. Impact of rituximab on stem cell mobilization following ACVBP 
regimen in poor-risk patients with diffuse large B-cell lymphoma: results 
from a large cohort of patients. Transfusion. 2013;53:115–22.
 9. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell 
recovery following rituximab-based therapy is associated with perturba-
tions in stromal derived factor-1 and granulocyte homeostasis. Blood. 
2005;106:795–802.
 10. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, et al. Effect 
of rituximab on peripheral blood stem cell mobilization and engraftment 
kinetics in non-Hodgkin’s lymphoma patients. Bone Marrow Transplant. 
2003;32:139–43.
 11. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, et al. Effects of 
pretransplantation treatment with rituximab on outcomes of autologous 
stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 
2004;22:4561–6.
 12. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, et al. A high incidence 
of late-onset neutropenia following rituximab-containing chemotherapy 
as a primary treatment of CD20-positive B-cell lymphoma: a single-
institution study. Ann Oncol. 2007;18:364–9.
 13. Papajik T, Pikalova Z, Raida L, Skoumalova I, Vondrakova J, Faber E, et al. 
Rituximab does not adversely affect the stem cell mobilization and 
engraftment after high-dose therapy and autologous transplantation in 
patients with diffuse large B-cell lymphoma in first complete or partial 
remission. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 
2009;153:211–4.
 14. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, et al. 
Impact of pre-transplant rituximab on survival after autologous hemat-
opoietic stem cell transplantation for diffuse large B-cell lymphoma. Biol 
Blood Marrow Transplant. 2009;15:1455–64.
 15. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H, et al. 
Factors affecting autologous peripheral blood stem cell collection in 
patients with relapsed or refractory diffuse large cell lymphoma and 
Hodgkin lymphoma: a single institution result of 168 patients. Leuk 
Lymphoma. 2008;49:769–78.
 16. Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, et al. Phase II study 
of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) 
therapy for newly diagnosed patients with low- and low-intermediate 
risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clini-
cal Oncology Group Study, JCOG9508. Int J Hematol. 2012;96:74–83.
 17. Shi YK, Yang S, Han XH, Ma J, Ren HY, Cen XN, et al. A prospective multi-
center study of rituximab combined with high-dose chemotherapy and 
autologous peripheral blood stem cell transplantation for aggressive 
B-cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2009;31:592–6 (in 
Chinese).
 18. Han X, Ma L, Zhao L, He X, Liu P, Zhou S, et al. Predictive factors for 
inadequate stem cell mobilization in Chinese patients with NHL 
and HL: 14-year experience of a single-center study. J Clin Apher. 
2012;27:64–74.
 19. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP+ 
fixed dose G-CSF as autologous peripheral blood stem cell mobilization 
regimen in patients with relapsed or refractory diffuse large cell and 
Hodgkin’s lymphoma: a single institution result of 127 patients. Bone 
Marrow Transplant. 2006;37:277–82.
 20. Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource 
utilization after stem cell mobilization failure in patients with multiple 
myeloma and lymphoma. Bone Marrow Transplant. 2010;45:1396–403.
 21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. 
Report of an international workshop to standardize response criteria for 
Page 9 of 9Shi et al. Chin J Cancer  (2015) 34:52 
non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. 
J Clin Oncol. 1999;17:1244.
 22. National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) 2010. Version 4.03. Washington, DC: US Department of 
Health and Human Services. Available at: http://evs.nci.nih.gov/ftp1/
CTCAE/About.html. Accessed 16 July 2015.
 23. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. 
Rituximab and ICE as second-line therapy before autologous stem cell 
transplantation for relapsed or primary refractory diffuse large B-cell 
lymphoma. Blood. 2004;103:3684–8.
 24. Wood WA, Whitley J, Goyal R, Brown PM, Sharf A, Irons R, et al. Effective-
ness of etoposide chemomobilization in lymphoma patients undergoing 
auto-SCT. Bone Marrow Transplant. 2013;48:771–6.
 25. Wu Y, Jia Y, Xu J, Shuai X, Wu Y. Fatal interstitial lung disease induced by 
rituximab-containing chemotherapy, treatment with TNF-α antagonist 
and cytokine profiling: a case-report and review of the literature. J Clin 
Pharm Ther. 2013;38:249–53.
 26. Kong H, Wang Y, Zeng X, Zhu Q, Xie W, Dai S. Involvement of NLRP3 
inflammasome in rituximab-induced interstitial lung disease: a case 
report. J Clin Pharm Ther. 2014;39:691–4.
 27. Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, 
et al. Factors associated with granulocyte colony-stimulating factor-
induced peripheral blood stem cell yield in healthy donors. Vox Sang. 
2005;89:229–35.
 28. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimiz-
ing autologous stem cell mobilization strategies to improve patient out-
comes: consensus guidelines and recommendations. Biol Blood Marrow 
Transplant. 2014;20:295–308.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
